GT Biopharma (GTBP)
NASDAQ:GTBP
Want to see GTBP full AI Analyst Report?
GTBP Stock Chart & Stats
$0.73
-$0.23(-8.01%)
At close: 4:00 PM EST
$0.73
-$0.23(-8.01%)
Day’s Range― - ―
52-Week Range$0.26 - $3.85
Previous CloseN/A
Volume15.05K
Average Volume (3M)1.63M
Market Cap
$9.72M
Enterprise Value-$3.92M
Total Cash (Recent Filing)$6.81M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.43
Next Earnings
May 18, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.22
Shares Outstanding31,553,892
10 Day Avg. Volume1,818,785
30 Day Avg. Volume1,629,462
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.75
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market Cap-0.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.11
Forecast
1Y Price Target
$3.00Price Target Upside310.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.7
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Immuno-oncology PipelineGT Biopharma’s concentrated strategy on NK cell–engaging biologics and engineered TriKE candidates represents a durable fundamental strength. A focused platform can create deep technical expertise, streamline R&D priorities, and generate multiple program opportunities, supporting long-term clinical value creation if trials succeed.
Low Financial LeverageMinimal debt exposure materially reduces bankruptcy and interest-rate risks, giving management flexibility to fund development via equity or partnerships. For a pre-revenue biotech, low leverage preserves optionality to pursue strategic collaborations or milestone deals without near-term fixed-payment obligations.
Academic Clinical CollaborationA formal university-sponsored Phase 1a/1b trial provides external validation, structured IND support, and operations sharing. Academic sponsorship can speed enrolment, enable publications, and de-risk development pathways—strengthening credibility and potentially improving partner or investor interest over the medium term.
Bears Say
No Revenue And Persistent LossesSustained lack of product revenue and recurring large losses indicate the company remains fully reliant on financing to operate. Over multiple reporting periods this undermines self-sustainability, raises execution risk for clinical programs, and lengthens the timeline before commercialization can offset expenses.
Eroding Equity BaseA shrinking and at-times negative equity base erodes the company’s financial buffer against setbacks. Continued capital erosion increases the probability of dilution or urgent financing, which can constrain strategic decision-making and impair investor returns over the medium term if R&D milestones are delayed.
Consistent Cash BurnOngoing negative operating and free cash flow signals a steady cash drain that necessitates new capital or cost reduction. Persistent burn rates can compress runway, force financing under unfavorable terms, and slow program progression if funding gaps intervene, posing a material execution risk for clinical timelines.
GT Biopharma News
GTBP FAQ
What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest stock price was $0.26 and its highest was $3.85 in the past 12 months.
What is GT Biopharma’s market cap?
GT Biopharma’s market cap is $9.72M.
When is GT Biopharma’s upcoming earnings report date?
GT Biopharma’s upcoming earnings report date is May 18, 2026 which is in 17 days.
How were GT Biopharma’s earnings last quarter?
GT Biopharma released its earnings results on Apr 01, 2026. The company reported -$2.22 earnings per share for the quarter, missing the consensus estimate of -$0.22 by -$2.
Is GT Biopharma overvalued?
According to Wall Street analysts GT Biopharma’s price is currently Undervalued.
Does GT Biopharma pay dividends?
GT Biopharma does not currently pay dividends.
What is GT Biopharma’s EPS estimate?
GT Biopharma’s EPS estimate is -0.08.
How many shares outstanding does GT Biopharma have?
GT Biopharma has 31,553,892 shares outstanding.
What happened to GT Biopharma’s price movement after its last earnings report?
GT Biopharma reported an EPS of -$2.22 in its last earnings report, missing expectations of -$0.22. Following the earnings report the stock price went up 0.245%.
Which hedge fund is a major shareholder of GT Biopharma?
Currently, no hedge funds are holding shares in GTBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GT Biopharma
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
GTBP Stock 12 Month Forecast
Average Price Target
$3.00
▲(310.96% Upside)
Technical Analysis
Theriva Biologics
―
Revelation Biosciences
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Azitra Inc
―
Ownership Overview
2.71%
Insiders
0.11% Mutual Funds
0.45% Other Institutional Investors
95.30% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---